


# <u>Mechanisms of action</u> of monoclonal antibodies


## Antibody







Google Immagini








#### Aminoacid variability in antibody sequence




Copyright © 2009 by Saunders, an imprint of Elsevier, Inc. All rights reserved.

#### Antigen/antibody complex




## Antigenic determinant (epitope)




Abbas et al: Cellular and Molecular Immunology, Updated 6th Edition. Copyright © 2009 by Saunders, an imprint of Elsevier, Inc. All rights reserved.

#### Antigen/antibody complex on cell membrane



Abbas et al: Cellular and Molecular Immunology, Updated 6th Edition. Copyright © 2009 by Saunders, an imprint of Elsevier, Inc. All rights reserved.

#### secreted and membrane antibodies



Abbas et al: Cellular and Molecular Immunology, Updated 6th Edition. Copyright © 2009 by Saunders, an imprint of Elsevier, Inc. All rights reserved.

class	subclass	plasma concentration (mg/ml)	halflife in plasma (days)	Secreted form
IgA	1,2	3,5	6	IgA (dimer) Monomer, dimer, trimer Ca1 Ca2 Ca2 Ca2 Ca2 Caai
lgD	-	-	3	-
IgE	_	0,05	2	IgE C:1 Monomer
lgG	1-4	13,5	23	IgG1 VH Monomer
IgM	_	1,5	5	lgM Cμ1 Pentamers, hexa mers Cμ3 Cμ4


Antibody Isotope	Isotype-specific effector functions	
IgG	<ul> <li>Opsonization of antigens for phagocytosis by macrophages and neutrophils</li> <li>Activation of the classical pathway of complement</li> <li>Antibody-dependent cell-mediated cytotoxicity mediated by natural killer cells</li> <li>Neonatal immunity: transfer of maternal antibody across the placenta and gut</li> <li>Feedback inhibition of B cell activation</li> </ul>	
IgM	<ul> <li>Activation of the classical pathway of complement</li> <li>Antigen receptor of naive B lymphocytes</li> </ul>	
IgA	<ul> <li>Mucosal immunity: secretion of IgA into the lumens of the gastrointestinal and respiratory tracts</li> <li>Activation of complement by the lectin pathway or by the alternative pathway</li> </ul>	
IgE	Mast cell degranulation (immediate hypersensitivity reactions)	
IgD	Antigen receptor of naive B lymphocytes	

FcR	Affinity for immunoglobulin	Cell Distribution	Function
Fcγ <b>RI (CD64)</b>	High (Kd ~ 10 <sup>-9</sup> M) binds IgG1 and IgG3	Macrophages, neutrophils; also eosinophils	Phagocytosis, activation of phagocytes
FcγRIIA (CD32)	Low (Kd > 10-7 M)	Macrophages, neutrophils; eosinophils, platelets	Phagocytosis; cell activation (inefficient)
FcγRIIB (CD32)	Low (Kd > 10 <sup>-7</sup> M)	B lymphocytes, dendritic cells, macrophages	Feedback inhibition of B cells, macrophages, dendritic cells
FcγRIIIA (CD16)	Low (Kd > 10 <sup>-6</sup> M)	NK cells	Antibody-dependent cell-mediated cytotoxicity
Fc y RIIIB (CD16)	Low (Kd > 10 <sup>-6</sup> M) GPI-linked protein	Neutrophils, other cells	Phagocytosis (inefficient)
Fc $arepsilon$ RI	High (Kd > 10 <sup>-10</sup> M) binds monomeric IgE	Mast cells, basophils, eosinophils	Cell activation (degranulation)
Fc ε RII (CD23)	Low (Kd > 10 <sup>-7</sup> M)	B lymphocytes, eosinophils, Langerhans cells	Unknown
FcαR (CD89)	Low (Kd > 10 <sup>-6</sup> M)	Neutrophils, eosinophils, monocytes	Cell activation?

## <u>Characteristics of an antibody</u>


- $\cdot$  Specificity in its action
- Biodistribution/halflife
- Activation of immune system


## Immune response



Copyright © 2009 by Saunders, an imprint of Elsevier, Inc. All rights reserved.


# B lymphocytes and plasma cells






Abbas et al: Cellular and Molecular Immunology, Updated 6th Edition. Copyright © 2009 by Saunders, an imprint of Elsevier, Inc. All rights reserved.

Timing for antibody production



Abbas et al: Cellular and Molecular Immunology, Updated 6th Edition. Copyright © 2009 by Saunders, an imprint of Elsevier, Inc. All rights reserved.

## Antibody engineering



# Types of antibodies/antibody fragments

- 1. Antagonist/Blocker
- 2. Agonist
- 3. Immuno-activator

# 1. Blocking antibodies

An antibody able to bind an antigen and <u>neutralize its</u> <u>function</u>

# Examples of neutralizing antibodies used in clinic

- 1. Natalizumab: humanized anti-CD49d (multiple sclerosis)
- 2. Eculizumab: humanized (IgG4) anti-C5 (PNH, Hemolytic Uremic syndrome, glomerulonephritis)
- 3. Bevacizumab: humanized anti-VEGF (colon-rectal cancer, lung carcinoma, other solid tumors, macula degeneration)
- 4. Cetuximab: chimeric anti-EGFR (colon-rectal cancer)
- 5. Infliximab: chimeric anti-TNFalfa (Rheumatoid arthritis, Crohn disease and other inflammatory diseases)
- 6. Adalimumab: human anti-TNFalfa (Rheumatoid arthritis, Crohn disease and other inflammatory diseases)
- 7. Pembrolizumab: humanized anti-PD1 (cancer immunotherapy)

# 2. Agonistic antibodies

Antibodies able to bind and activate its target (usually cell membrane receptors)

These antibodies can be used to induce cell apoptosis (for cancer therapy) or to induce immune cell proliferation (in immune deficiencies)

# Examples of agonistic antibodies

- 1. Trastuzumab: humanized anti-HER2 (breast cancer)
- 2. Tigatuzumab: humanized anti-TRAIL-R1 (breast cancer)
- 3. humanized anti-IL2R (infections, immune deficiencies, cancer immunotherapy)

## 3. Immune-activator antibodies

Antibodies able to bind their target (cell membrane receptors) and activate immune response.

Used in cancer immunotherapy (for the killing of cancer cells) or in autoimmune diseases (to eliminate B lymphocytes and, as a consequence, the production of autoantibodies)


## Examples of immune-activators antibodies


- 1. Rituximab: chimeric anti-CD20 (B cell lymphoma and leukemia, rheumatoid arthritis)
- 2. Alemtuzumab: humanized anti-CD52 (B or T cell lymphoma and leukemia)
- 3. Ofatumumab: human (IgG1) anti-CD20 (B cell lymphoma and leukemia)
- 4. Trastuzumab: humanized anti-HER2 (breast cancer)
- 5. cMOV18 e cMOV19: umanizzati anti-folate receptor (alpha isoform) (Ovarian cancer)


class	subclass	plasma concentration (mg/ml)	halflife in plasma (days)	Secreted form
IgA	1,2	3,5	6	IgA (dimer) Monomer, dimer, trimer Ca1 Ca2 Ca2 Ca2 Ca2 Caai
lgD	-	-	3	-
IgE	_	0,05	2	IgE C:1 Monomer
lgG	1-4	13,5	23	IgG1 VH Monomer
IgM	_	1,5	5	lgM Cμ1 Pentamers, hexa mers Cμ3 Cμ4

Antibody Isotope	Isotype-specific effector functions	
IgG	<ul> <li>Opsonization of antigens for phagocytosis by macrophages and neutrophils</li> <li>Activation of the classical pathway of complement</li> <li>Antibody-dependent cell-mediated cytotoxicity mediated by natural killer cells</li> <li>Neonatal immunity: transfer of maternal antibody across the placenta and gut</li> <li>Feedback inhibition of B cell activation</li> </ul>	
IgM	<ul> <li>Activation of the classical pathway of complement</li> <li>Antigen receptor of naive B lymphocytes</li> </ul>	
IgA	<ul> <li>Mucosal immunity: secretion of IgA into the lumens of the gastrointestinal and respiratory tracts</li> <li>Activation of complement by the lectin pathway or by the alternative pathway</li> </ul>	
IgE	Mast cell degranulation (immediate hypersensitivity reactions)	
IgD	Antigen receptor of naive B lymphocytes	


## Immune-activator monoclonal antibodies: CDC (Complement-Dependent Cytotoxicity)









Copyright © 2009 by Saunders, an imprint of Elsevier, Inc. All rights reserved.




Abbas et al: Cellular and Molecular Immunology, Updated 6th Edition. Copyright © 2009 by Saunders, an imprint of Elsevier, Inc. All rights reserved.




Abbas et al: Cellular and Molecular Immunology, Updated 6th Edition. Copyright © 2009 by Saunders, an imprint of Elsevier, Inc. All rights reserved.




Copyright © 2009 by Saunders, an imprint of Elsevier, Inc. All rights reserved.






Abbas et al: Cellular and Molecular Immunology, Updated 6th Edition. Copyright © 2009 by Saunders, an imprint of Elsevier, Inc. All rights reserved.




Seva et al, Nat Comm, 2016




FcR	Affinity for immunoglobulin	Cell Distribution	Function
Fcγ <b>RI (CD64)</b>	High (Kd ~ 10 <sup>-9</sup> M) binds IgG1 and IgG3	Macrophages, neutrophils; also eosinophils	Phagocytosis, activation of phagocytes
FcγRIIA (CD32)	Low (Kd > 10 <sup>-7</sup> M)	Macrophages, neutrophils; eosinophils, platelets	Phagocytosis; cell activation (inefficient)
FcγRIIB (CD32)	Low (Kd > 10 <sup>-7</sup> M)	B lymphocytes, dendritic cells, macrophages	Feedback inhibition of B cells, macrophages, dendritic cells
FcγRIIIA (CD16)	Low (Kd > 10 <sup>-6</sup> M)	NK cells	Antibody-dependent cell-mediated cytotoxicity
FcγRIIIB (CD16)	Low (Kd > 10 <sup>-6</sup> M) GPI-linked protein	Neutrophils, other cells	Phagocytosis (inefficient)
Fc $arepsilon$ RI	High (Kd > 10 <sup>-10</sup> M) binds monomeric IgE	Mast cells, basophils, eosinophils	Cell activation (degranulation)
Fc ε RII (CD23)	Low (Kd > 10 <sup>-7</sup> M)	B lymphocytes, eosinophils, Langerhans cells	Unknown
FcαR (CD89)	Low (Kd > 10 <sup>-6</sup> M)	Neutrophils, eosinophils, monocytes	Cell activation?


FcR	Affinity for immunoglobulin	Cell Distribution	Function
Fcγ <b>RI (CD64)</b>	High (Kd ~ 10 <sup>-9</sup> M) binds IgG1 and IgG3	Macrophages, neutrophils; also eosinophils	Phagocytosis, activation of phagocytes
FcγRIIA (CD32)	Low (Kd > 10 <sup>-7</sup> M)	Macrophages, neutrophils; eosinophils, platelets	Phagocytosis; cell activation (inefficient)
FcγRIIB (CD32)	Low (Kd > 10 <sup>-7</sup> M)	B lymphocytes, dendritic cells, macrophages	Feedback inhibition of B cells, macrophages, dendritic cells
FcγRIIIA (CD16)	Low (Kd > 10 <sup>-6</sup> M)	NK cells	Antibody-dependent cell-mediated cytotoxicity
FcγRIIIB (CD16)	Low (Kd > 10 <sup>-6</sup> M) GPI-linked protein	Neutrophils, other cells	Phagocytosis (inefficient)
Fc $arepsilon$ RI	High (Kd > 10 <sup>-10</sup> M) binds monomeric IgE	Mast cells, basophils, eosinophils	Cell activation (degranulation)
Fc ε RII (CD23)	Low (Kd > 10 <sup>-7</sup> M)	B lymphocytes, eosinophils, Langerhans cells	Unknown
FcαR (CD89)	Low (Kd > 10 <sup>-6</sup> M)	Neutrophils, eosinophils, monocytes	Cell activation?




Abbas et al: Cellular and Molecular Immunology, Updated 6th Edition. Copyright © 2009 by Saunders, an imprint of Elsevier, Inc. All rights reserved.


### Immune-activator monoclonal antibodies: ADCC (Antibody-Dependent Cellular Cytotoxicity)









FcR	Affinity for immunoglobulin	Cell Distribution	Function
Fc γ <b>RI (CD64)</b>	High (Kd ~ 10 <sup>-9</sup> M) binds IgG1 and IgG3	Macrophages, neutrophils; also eosinophils	Phagocytosis, activation of phagocytes
FcyRIIA (CD32)	Low (Kd > 10 <sup>-7</sup> M)	Macrophages, neutrophils; eosinophils, platelets	Phagocytosis; cell activation (inefficient)
FcγRIIB (CD32)	Low (Kd > 10 <sup>-7</sup> M)	B lymphocytes, dendritic cells, macrophages	Feedback inhibition of B cells, macrophages, dendritic cells
FcγRIIIA (CD16)	Low (Kd > 10 <sup>-6</sup> M)	NK cells	Antibody-dependent cell-mediated cytotoxicity
FcγRIIIB (CD16)	Low (Kd > 10 <sup>-6</sup> M) GPI-linked protein	Neutrophils, other cells	Phagocytosis (inefficient)
Fc $arepsilon$ RI	High (Kd > 10 <sup>-10</sup> M) binds monomeric IgE	Mast cells, basophils, eosinophils	Cell activation (degranulation)
Fc ε RII (CD23)	Low (Kd > 10 <sup>-7</sup> M)	B lymphocytes, eosinophils, Langerhans cells	Unknown
FcαR (CD89)	Low (Kd > 10 <sup>-6</sup> M)	Neutrophils, eosinophils, monocytes	Cell activation?



Copyright © 2004 Pearson Education, Inc., publishing as Benjamin Cummings.







(b)

#### (a)


Copyright © 2004 Pearson Education, Inc., publishing as Benjamin Cummings.


### Immune-activator monoclonal antibodies: Phagocytosis







Abbas et al: Cellular and Molecular Immunology, Updated 6th Edition. Copyright © 2009 by Saunders, an imprint of Elsevier, Inc. All rights reserved.









## Immune-activator monoclonal antibodies: CDCC (Complement-Dependent Cellular Cytotoxicity)





#### Effector mechanisms of monoclonal antibodies



Modified from Gelderman et al. Trends in Immunol, 2004

# <u>Mechanisms of action of</u> <u>immune-activator antibodies</u>

CITOTOSSICITA' CELLULARE ANTICORPO DIPENDENTE (ADCC)	Mediata in particolare dalle cellule NK, che tramite il recettore FcgRIII riconosce la porzione Fc dell'anticorpo. Liberazione del contenuto dei granuli citoplasmatici (perforine, granzimi).	
OPSONIZZAZIONE E FAGOCITOSI	Gli anticorpi rivestono la cellula tumorale e ne favoriscono l'internalizzazione da parte dei fagociti che riconoscono la porzione Fc mediante i recettori per Fc.	
APOPTOSI	Da aggregazione dell'antigene sulla superficie cellulare.	
ATTIVAZIONE DELLA VIA CLASSICA DEL COMPLEMENTO	Legame di C1q all'Fc dell'anticorpo; lisi cellulare (CDC); i prodotti generati dall'attivazione del complemento (anafilotossine e opsonine) inducono flogosi e promuovono la fagocitosi.	